統合腫瘍学ジャーナル

A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology Using Natural Tumor Sensitizers for Treatment Of Triple Negative Breast Cancer Patients

Abstract

Raghu Pandurangi

Statement of the Problem: Cancer cells have inherent ability to circumvent intervention irrespective of the nature of intervention by desensitizing themselves through a) activating survival pathways (e.g. NF-kB, PARP) and downregulating cell death pathways (e.g. CD95, ASK1) simultaneously. The situation is worse for triple negative breast cancer (TNBC) patients who have no option except non-specific chemotherapy, despite high off-target toxicity. No targeted therapy is approved for TNBC treatment since TNBC lack biomarkers (e.g. PR, ER and HER2 negative) for which drugs are designed. This puts TNBC patients on an enormous risk for survival. The purpose of this study is to make FDA approved drugs better using AAAPT technology.